Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer

Cancer Journal from Scientific American

Volumn 6, Issue SUPPL. 1, 2000, Pages

  Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; TUMOR ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOPHENOL MONOOXYGENASE; SYNTHETIC PEPTIDE; MART1 ANTIGEN; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILD; CONFERENCE PAPER; DRUG SAFETY; FEMALE; HUMAN; IMMUNITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TUMOR REGRESSION; CLINICAL TRIAL; IMMUNIZATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM PROTEINS; NEOPLASMS;

EID: 0033847583     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Morgan DA, Ruscetti FW, Gallo RG. Selective in vitro growth of T-lymphocytes from normal bone marrow. Science 1976;193:1007-1008.
2. Taniguchi T, Matsui H, Fujita T et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983;302:305-310.
3. Rosenberg SA, Grimm FA, McGrogan M et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984;223:1412-1414.
4. Rosenberg SA, Mulé JJ, Spiess PJ et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169-1188.
5. Rosenberg SA, Yang JC, White DE et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998;228:307-319.
6. Schwartzentruber DJ. Biologic therapy with interleukin-2. In: DeVita V, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. 2nd ed. Philadelphia: JB Lippincott Co, 1995:235-249.
7. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998;83:797-805.
8. Van Pel A, van der Bruggen P, Coulie PG et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-250.
9. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-182.
10. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-287.
11. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-3519.
12. Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-6462.
13. Robbins PF, el-Gamil M, Kawakami Y et al. Recognition of tyrosinase by rumor-infiltrating lymphocytes from a patient responding to immunotherapy [published erratum appears in Cancer Res 1994;54:3952]. Cancer Res 1994;54:3124-3126.
14. Robbins PF, el-Gamil M, Li YF et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-5950.
15. Wang RF, Robbins PF, Kawakami Y et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995;181:1261]. J Exp Med 1995;181:799-804.
16. Wang RF, Parkhurst MR, Kawakami Y et al. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183:1131-1140.
17. Wang RF, Appella E, Kawakami Y et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184:2207-2216.
18. Wang RF, Johnston SL, Zeng G et al. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 1998;161:3598-3606.
19. Robbins PF, el-Gamil M, Li YF et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-1192.
20. Wang RF, Wang X, Atwood AC et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999;284:1351-1354.
21. Pieper R, Christian RE, Gonzales MI et al. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med 1999;189:757-766.
22. Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med 1999;189:1659-1668.
23. Coulie PG, Brichard V, Van Pel A et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
24. Brichard V, Van Pel A, Wolfel T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
25. Rosenberg S, White D. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;19:81-84.
26. Robbins PF, el-Gamil M, Li YF et al. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol 1997;159:303-308.
27. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-1918.
28. Parkhurst MR, Fitzgerald EB, Southwood S et al. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998;58:4895-4901.
29. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gpl00 modified at HLA-A*0201-binding residues. J Immunol 1996;157:2539-2548.
30. Cormier JN, Salgaller ML, Prevette T et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
31. Salgaller ML, Marincola FM, Cormier JN et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-4757.
32. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998;4:321-327.
33. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999;163:1690-1695.
34. Rosenberg, SA. Keynote address: perspectives on the use of interleukin-2 in cancer treatments. Cancer J Sci Am 1997;3[suppl 1]:S2-S6.